Research programme: monoclonal antibody-based therapeutics - John Hopkins University/Morphotek

Drug Profile

Research programme: monoclonal antibody-based therapeutics - John Hopkins University/Morphotek

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator John Hopkins University; Morphotek
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Immunoconjugates; Ketones; Macrocyclic compounds; Monoclonal antibodies; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 06 Sep 2017 Morphotek enters into a collaboration with John Hopkins University for development of monoclonal antibody-based therapeutics
  • 06 Sep 2017 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top